Zadaxin thymosin alpha 1 data

SCLN (San Mateo, Calif.) announced an interim analysis of an ongoing Phase III trial in Taiwan, enrolling 158 patients. At the 12-month time point (in an 18-month total observation time), viral DNA clearance and clearance of the hepatitis B e antigen is 31 percent in the group treated for six months, 24 percent in those treated for 12 months, and 17 percent in the group that did not receive the agent (about 25 patients per group). ...